Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.
Saved in:
| Title: | Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis. |
|---|---|
| Authors: | Holmstroem RB; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Teisner AS; Department of Medical Gastroenterology and Hepatology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Sweep MWD; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.; Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, Netherlands., Noringriis IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Khan S; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Aagaard NK; Department of Medical Gastroenterology and Hepatology, Aarhus University Hospital, Aarhus, Denmark., Karlström J; Division of Oncology, Department of Clinical Science, Faculty of Medicine, Lund University, Lund, Sweden., Jurlander RS; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Sohlin JE; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Monberg TJ; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Vestergaard C; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Stoltenborg Granhøj J; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Stenbøg P; Department of Medical Gastroenterology and Hepatology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Toxvaerd A; Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Hansen AB; Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Bjerring PN; Department of Transplantation and Digestive Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Capital Region of Denmark, Denmark., Lorentzen T; Department of Medical Gastroenterology and Hepatology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark.; Department of Radiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Thielsen P; Department of Medical Gastroenterology and Hepatology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark.; Department of Radiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Bol K; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.; Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, Netherlands., Jonsson G; Division of Oncology, Department of Clinical Science, Faculty of Medicine, Lund University, Lund, Sweden., Ellebaek E; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Capital Region of Denmark, Denmark Inge.Marie.Svane@regionh.dk. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Mar 05; Vol. 14 (3). Date of Electronic Publication: 2026 Mar 05. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
